Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 Versus Standard of Care Valaciclovir in Patients With Chronic Recurrent Anogenital HSV-2 Infection

NCT04165122 is registered in ClinicalTrials.gov with Heidelberg ImmunoTherapeutics GmbH as lead sponsor.

NCT NCT04165122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04165122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 Versus Standard of Care Valaciclovir in Patients With Chronic Recurrent Anogenital HSV-2 Infection
Lead sponsor
Heidelberg ImmunoTherapeutics GmbH
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2019
Completion date
November 1, 2021
Enrollment
122 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

herpes genitalis